Background
==========

Use of antiretrovirals can adversely affect serum lipid levels and contribute to cardiovascular risk, an emerging concern among HIV-infected patients. \[[@B1],[@B2]\] Therefore, careful comparisons of the effects of commonly used antiretrovirals on serum lipids are needed. Efavirenz (EFV) and atazanavir (TAZ) are two commonly used antiretrovirals. The results of a phase 3 study comparing EFV and TAZ based regimens demonstrate similar virologic efficacy with the use of either agent, though EFV use resulted in dyslipidemia while TAZ use did not. \[[@B3]\] However, the current treatment paradigm favors the use of TAZ in combination with low dose ritonavir (boosted TAZ) and not unboosted TAZ.\[[@B4]\] Since, the addition of ritonavir to TAZ results in dyslipidemia \[[@B5]\], there is a need to compare and contrast the magnitude of the effects of boosted TAZ and EFV based regimens on serum lipids. To this end, we utilized data from a racially diverse group of HIV-infected individuals with the specific aims of comparing the effects of boosted TAZ and EFV on serum lipids. In this study we observed beneficial changes, namely declines in total cholesterol (TC)/high density lipoprotein cholesterol (HDL) ratio and increases in HDL-c, in serum lipids with all three regimens (unboosted TAZ, boosted TAZ, and EFV)

Methods
=======

Study population
----------------

Data were collected from participants enrolled in three independent ongoing prospective cohort studies: the Multicenter AIDS Cohort Study (MACS), the Women\'s Interagency HIV Study (WIHS), and United States Navy beneficiaries followed at two of three Navy HIV Evaluation and Treatment Units. Recruitment and follow-up procedures for all three patient groups have been previously described. \[[@B6]-[@B8]\] Eligible subjects initiated regimens of two or more nucleoside reverse transcriptase inhibitors (NRTI) with either 1) EFV or 2) TAZ or boosted TAZ, using these criteria 1,020 EFV and 655 TAZ initiators were identified. Excluding initiators who did not have lipids measured both pre and post initiation (430 EFV and 108 TAZ), those missing information on antiretroviral use during the study period (41 EFV and 50 TAZ), those using both agents at the pre visit (137 EFV and 179 TAZ), or using lipid lowering therapy at the pre or first post visit (32 EFV and 37 TAZ), 380 EFV and 281 TAZ initiators comprised our final study population. Complete antiretroviral history including start and stop dates were determined from chart review, electronic pharmacy records, or self-report assessed using questionnaires and photo cards. Individuals were followed up to the first occurrence of 1) discontinuation of EFV or TAZ (29% EFV, 30% TAZ), 2) initiation of lipid-lowering therapy (4% EFV, 1% TAZ), or 3) last lipid measurement within two years of initiating EFV/TAZ (67% EFV, 68% TAZ). There was no difference in censoring between the two ARV groups (p = 0.21). EFV or TAZ was used \<1 to 6 months prior to the first post visit for 76% of participants, 6--12 months for 19%, and 12--24 months for 5%.

Outcome ascertainment
---------------------

MACS began routine measurement of serum lipids for all participants in April 1999; WIHS began in April 2004. Baseline levels were measured retrospectively for selected MACS participants, and for all WIHS participants seen between October 2001 and March 2004. Navy participants had lipids measured at all visits. Both MACS and WIHS used a central laboratory, while the Navy participants used their hospital laboratories for lipid measures. Three continuous and two binary outcomes based on the updated National Cholesterol Education Program (NCEP) ATP III Guidelines \[[@B9]\] were defined: 1) high-density lipoprotein cholesterol (HDL-c measured in mg/dL), 2) non-HDL-c (mg/dL) calculated as total cholesterol (TC) minus HDL-c, 3) natural log-transformed TC to HDL-c ratio, 4) low HDL-c (\<40 vs. ≥ 40 mg/dL), and 5) desirable TC (\<200 vs. ≥ 200 mg/dL).

Statistical methods
-------------------

Multivariate linear regression was used to estimate adjusted mean differences between treatment groups for HDL-c, non-HDL-c, and log TC to HDL-c ratio; multivariate log-linear regression was used to estimate prevalence ratios for low HDL-c and desirable TC. For each outcome, two models with different potential confounders were included. Model 1 adjusted for sex, race/ethnicity, age at EFV/TAZ initiation, history of diabetes mellitus or thyroid dysfunction, baseline hepatitis C virus antibody status, pre-initiation HDL-c and non-HDL-c, CD4+ cell count, HIV-1 viral load, pre-initiation ART- and class- (NNRTI/PI) naïve status, years of HAART exposure and follow up time. In model 2, we further adjusted for post-initiation CD4+ count and HIV-1 viral load and type of NRTI backbone. Two potential a priori effect modifiers of regimen with dyslipidemia outcomes were also investigated: (a) follow-up time (time elapsed between the date of EFV/TAZ initiation and the date lipids were collected) and (b) race/ethnicity. We specifically evaluated the role of race and ethnicity, given recent reports that suggest the effects of antiretrovirals on serum lipids are modified by host characteristics including race. \[[@B10]\]

For each model, generalized estimating equation methods (GEE) were used to account for within-person correlation of repeated measurements. Data were complete for all cofactors for 357 (94%) of EFV and 259 (94%) of TAZ users; (single-chain) Markov-chain Monte Carlo multiple-imputation methods were used to complete missing covariate data. \[[@B11]\]

Results
=======

The study population consisted of 380 EFV initiators and 281 TAZ initiators (79% of whose regimens were boosted), racial minorities (47% African-Americans and 16% Hispanics) and women (48%) were well represented. Table [1](#T1){ref-type="table"} provides the baseline characteristics of the two groups. Adjusted for baseline CD4 counts, follow-up time, regimen type, and sex, CD4+ cell counts increased on average by 57 cells per year. The proportion of individuals having an undetectable viral load (i.e. \< 80 copies/ml) increased from 18% to 63% among all subjects. At any point in time, on average, TAZ users had lower CD4+ cell count (-26, p = 0.05) and lower odds of an undetectable viral load (0.60, p \< 0.0001).

###### 

Baseline characteristics of 380 efavirenz and 281 atazanavir initiators.

  --------------------------------------------------------------------------------------------------------------
  Patient Characteristics\*                       Efavirenz initiators\   Atazanavir initiators\   P-value\*\*
                                                  (N = 380)               (N = 281)                
  ----------------------------------------------- ----------------------- ------------------------ -------------
  **Study site**                                                                                   \<0.0001

                                                                                                   

  Navy                                            32%                     25%                      

                                                                                                   

  MACS                                            33%                     15%                      

                                                                                                   

  WIHS                                            36%                     60%                      

                                                                                                   

                                                                                                   

                                                                                                   

  Male                                            63%                     38%                      \<0.0001

                                                                                                   

                                                                                                   

                                                                                                   

  **Race/Ethnicity**                                                                               \<0.0001

                                                                                                   

  Caucasian (Hispanic & Non Hispanic)             43%                     28%                      

                                                                                                   

  African-American (Hispanic & Non-Hispanic)      46%                     49%                      

                                                                                                   

  Hispanic (non-white, non-black) & other         11%                     22%                      

                                                                                                   

                                                                                                   

                                                                                                   

  Age at switch/initiation                        41 (34, 47)             41 (35, 46)              0.91

                                                                                                   

                                                                                                   

                                                                                                   

  **Medical History**                                                                              

                                                                                                   

  Diabetes Mellitus                               11%                     17%                      0.03

                                                                                                   

  Thyroid Disease                                 3%                      6%                       0.07

                                                                                                   

  Hepatitis C antibody status                     15%                     19%                      0.18

                                                                                                   

                                                                                                   

                                                                                                   

  **Treatment Characteristics**                                                                    

                                                                                                   

  HAART initiation date                           Aug 2001\               Dec 1998\                0.003
                                                  (Aug 97-Sep03)          (May 97-Sep 02)          

                                                                                                   

  ART-naïve at initiation                         34%                     12%                      \<0.0001

                                                                                                   

  Class-naïve at initiation                       80%                     30%                      \<0.0001

                                                                                                   

  Years of HAART exposure at initiation           0.5 (0.1, 2.9)          3.6 (1.2, 5.7)           \<0.0001

                                                                                                   

  Atazanavir regimen included Ritonavir                                   79%                      

                                                                                                   

                                                                                                   

                                                                                                   

  **HIV biomarkers prior to initiation**                                                           

                                                                                                   

  CD4+ cell count                                 332 (216, 464)          289 (202, 462)           0.11

                                                                                                   

  Log~10~HIV RNA                                  4.15 (2.65, 4.75)       4.01 (2.59,4.76)         0.42

                                                                                                   

  Viral load \<80 copies/mL                       19%                     17%                      0.50

                                                                                                   

                                                                                                   

                                                                                                   

  **Post-initiation HIV characteristics\*\*\***                                                    

                                                                                                   

  CD4+ cell count                                 434 (303, 581)          410 (241, 575)           0.02

                                                                                                   

  Log~10~HIV RNA                                  1.90 (1.90, 2.38)       1.90 (1.90, 2.51)        \<0.0001

                                                                                                   

  Viral load \<80 copies/mL                       68%                     58%                      0.0003

                                                                                                   

  NRTI backbone included                                                                           

                                                                                                   

    TDF or ABC & D4T, DDI, or AZT                 19%                     28%                      0.0003

                                                                                                   

   TDF or ABC but not D4T, DDI, or AZT            32%                     58%                      \<0.0001

                                                                                                   

   D4T, DDI, or AZT but not TDF or ABC            49%                     14%                      \<0.0001
  --------------------------------------------------------------------------------------------------------------

\* Median (IQR) for continuous characteristics \*\* From chi-square tests (categorical) or Wilcoxon rank sum test (continuous) \*\*\* Collapsed across all follow-up

The first two columns of Table [2](#T2){ref-type="table"} show the mean or prevalence of each of the outcomes at the baseline (pre-initiation) and post-initiation visits. The subsequent columns of Table [2](#T2){ref-type="table"} show the differences in post-initiation markers relative to those initiating EFV. There were no differences in the baseline TC, non HDL-c, or HDL-c among EFV and TAZ users. After adjusting for potential confounders, both boosted and unboosted TAZ initiators showed a smaller increase in HDL-c than EFV initiators. Those initiating boosted (but not unboosted) TAZ also showed lower non-HDL-c as compared to EFV initiators. All three regimens resulted in similar declines in TC/HDL ratios. The proportion of subjects who met study specified criteria for low HDL-c declined with all three regimens and was not statistically different among the three groups. Subjects meeting study specified criteria for desirable cholesterol were similar across treatment groups. The interaction between regimen type and follow-up time was not significant in any model.

###### 

Comparison of the changes in serum lipids following initiation of either Efavirenz or Atazanavir based regimens.

                                           Mean                                                                                                                                     
  ------------------------ --------------- ------------ ------ ---------------------------------- ------------------------------------- --------- --------------------------------- ---------
  **HDL-c (mg/dL)**        EFV             39           46     Ref                                Ref                                             Ref                               
                           Unboosted TAZ   39           42     -4                                 -3.92                                 0.003     -3.43                             0.008
                           Boosted TAZ     38           41     -5                                 -4.12                                 \<0.001   -4.00                             \<0.001
  **Non- HDL-c (mg/dL)**   EFV             131          136    Ref                                Ref                                             Ref                               
                           Unboosted TAZ   117          131    -5                                 -1.92                                 0.55      -1.08                             0.73
                           Boosted TAZ     126          125    -11                                -5.75                                 0.01      -4.57                             0.04
  **TC/HDL**               EFV             4.45         4.02   Ref                                Ref                                             Ref                               
                           Unboosted TAZ   4.45         4.10   1.99                               4.41                                  0.14      3.94                              0.19
                           Boosted TAZ     4.10         3.97   -1.24                              2.62                                  0.21      3.40                              0.11
                                                                                                                                                                                    
                                                                                                                                                                                    
                                                                                                                                                                                    
                                           Prevalence                                                                                                                               
  Binary Lipid Outcome     ARV Group       Pre          Post   Unadjusted Post Prevalence Ratio   Model 1\* Adjusted Prevalence Ratio   p-value   Model 2\*\* Adjusted Difference   p-value
                                                                                                                                                                                    
  **HDL\<40 (mg/dL)**      EFV             52%          33%    Ref                                Ref                                             Ref                               
                           Unboosted TAZ   55%          39%    1.18                               1.05                                  0.79      1.01                              0.95
                           Boosted TAZ     53%          42%    1.27                               1.18                                  0.18      1.19                              0.17
  **TC\<200 (mg/dL)**      EFV             74%          62%    Ref                                Ref                                                                               
                           Unboosted TAZ   85%          73%    1.18                               1.07                                  0.59      1.05                              0.71
                           Boosted TAZ     81%          78%    1.26                               1.16                                  0.09      1.13                              0.16

\* Adjusted for sex, race, age, history of chronic diseases, pre-initiation HDL and non-HDL cholesterol, CD4, HIV RNA, therapy, and follow-up time

\*\* In addition to variables above, also adjusted for post-initiation CD4, HIV RNA, and type of NRTI backbone

Changes in serum lipids varied by race; in comparison to Caucasians, mean post-initiation HDL-c was significantly higher (+5 mg/dL, p \< 0.0001) among African-Americans, while Hispanics had significantly lower mean non-HDL-c (-5 mg/dl, p = 0.04). In African-Americans, the TC/HDL ratio and proportion who met study specified criteria for low HDL-c were significantly lower by 8% (p \< 0.0001) and 34% (p = 0.0001) respectively. The TC/HDL was also significantly lower in Hispanics by 5% (p = 0.03). However, the interaction between regimen type and race was not significant in any model.

In a separate analysis to assess possible bias resulting from excluding individuals who had post-initiation lipids but were missing pre-initiation measures, we ran additional multivariate linear regression models using GEE methods for HDL-c and non-HDL-c, adjusting for sex, race, age, and follow-up time, first excluding those who were missing pre-initiation measures (MPM) and then including them. When the MPM individuals were excluded, TAZ users had 5.97 mg/dL lower HDL-c than EFV users (p \< 0.001); when they were included, TAZ users had 6.48 mg/dL lower HDL-c (p \< 0.001). For non-HDL-c, the differences were -7.46 mg/dL (p = 0.046) excluding MPM individuals and -13.86 mg/dL (p \< 0.001) including them

Discussion
==========

The results of our study are similar to those observed in a randomized clinical trial comparing EFV and unboosted TAZ in naïve patients.\[[@B3]\] In this study, those initiating EFV had greater increases in TC and HDL-c. Our results would suggest that the addition of low dose ritonavir to TAZ appears not to negate these effects. Interestingly, the use of all three regimens (EFV, boosted and unboosted TAZ) were associated with beneficial changes in serum lipids in comparison to baseline namely increases in HDL-c, and decreases in TC/HDL ratio. In addition, the proportion of patients who switched HDL-categories (low to normal) increased with all three regimens. However, in comparison to boosted TAZ-users, EFV-users had greater increases in both HDL and non-HDL-c. Whether differences in the class of lipids preferentially affected by these agents will influence the risk of future coronary artery disease is unknown and warrants study.

Given the racial diversity of the study population we were also able to evaluate the effects of these agents by race. African-Americans and Hispanics demonstrated a less atherogenic lipid profile in response to therapy with either agent. It\'s unlikely that lifestyle factors alone account for the differences we observed; genetic variations probably played a role. Differences in host genetic characteristics are known to influence levels of both EFV and TAZ and serum lipid levels independently. \[[@B12],[@B13]\] Increases in HDL-c and non HDL-c in response to ART are associated with polymorphisms in the cholesterol ester transfer protein and multi-drug resistance genes. \[[@B14]\] Thus far, pharmacogenetic studies have been conducted in racially homogeneous populations; futures studies should include racially representative population, to help explain these differences. \[[@B14],[@B15]\]

One possible criticism regarding our study is its observational design with the potential for selection bias and confounding by unmeasured variables. As described previously, we conducted a sub-group analysis in patients with missing pre-initiation lipid measures. Similar results were observed among those with and without pre-initiation measures, thereby indicating that a selection bias was probably not operational and further validating our results.

Conclusion
==========

In conclusion, clinicians treating HIV-infected patients can be reassured that the use of both boosted TAZ and EFV-based regimens results in a favorable lipid profile, as measured by changes in serum TC/HDL ratio. However, since subtle metabolic effects are likely to become increasingly important in decisions regarding optimal drug therapy in HIV-infected patients, future studies should explore the effects of drugs on lipoprotein subclasses and the effects of host genetics on metabolic profiles. \[[@B16]\]
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